Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the tumor. Giving paclitaxel together with sorafenib may
kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well paclitaxel works when given
together with or without sorafenib in treating patients with locally recurrent or metastatic
breast cancer.